ArticleSignal transduction and targeted therapy2026

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.

Herui Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.